Concepedia

Subir Goyal

SG

Statistics

Publications

26

Citations

860

H-Index

16

Active since

2013

Affiliations

Emory University(Current)

Northwestern University

University of North Carolina at Chapel Hill

The Ohio State University

Washington University in St. Louis

Subir Goyal is an author at Emory University specializing in medicine, oncology, and outcomes research.

ORCID

Top concepts

Publications per year

2013–2023

26

Publications

26

18F-fluciclovine-PET/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2/3 randomised controlled trial

Ashesh B. Jani, Eduard Schreibmann, Subir Goyal et al. · The Lancet · 2021 · 178 citations · Full text

, , +15

Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone

Timothy M. Schmidt, Benjamin G. Barwick, Nisha S. Joseph et al. · Blood Cancer Journal · 2019 · 163 citations · Full text

Mismatch Repair (MMR) Gene Alteration and BRAF V600E Mutation Are Potential Predictive Biomarkers of Immune Checkpoint Inhibitors in MMR-Deficient Colorectal Cancer

İbrahim Halil Şahin, Subir Goyal, Yoanna S Pumpalova et al. · The Oncologist · 2021 · 46 citations · Full text

MERTK activation drives osimertinib resistance in EGFR-mutant non–small cell lung cancer

Dan Yan, Justus M. Huelse, Dmitri Kireev et al. · Journal of Clinical Investigation · 2022 · 43 citations · Full text

Immune-Related Adverse Events as Clinical Biomarkers in Patients with Metastatic Renal Cell Carcinoma Treated with Immune Checkpoint Inhibitors

Dylan J. Martini, Subir Goyal, Yuan Liu et al. · The Oncologist · 2021 · 38 citations · Full text

1–5 of 26